Gynaecological neoplasia

ObsEva to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, August 3, 2021
Gynaecological neoplasia, Uterine fibroid, Endometriosis, Preterm birth, Ticker symbol, Gynaecology, Clinical medicine, Medicine

Details on the presentations can be found below.

Key Points: 
  • Details on the presentations can be found below.
  • ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health and pregnancy.
  • Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor.
  • ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol OBSV and on the SIX Swiss Exchange where it is trading under the ticker symbol OBSN.

Black Women's Health Advocates Applaud Legislation to Address the Uterine Fibroid Crisis

Retrieved on: 
Friday, July 23, 2021
Anatomy, Gynaecological neoplasia, Uterine fibroid, Clinical medicine, Medicine, Uterus, Fibroid, Uterine artery embolization, Adenomyosis

"Uterine fibroids are a health threat that urgently requires research, resources, and improved treatment options."

Key Points: 
  • "Uterine fibroids are a health threat that urgently requires research, resources, and improved treatment options."
  • "Uterine fibroids are a health threat that urgently requires research, community resources, and improved treatment options that preserve fertility.
  • BWHI supports this legislation because it will increase funding for uterine fibroid research and lead to new evidence-based treatments and cures for women of color."
  • "There is much more work to be done to address the uterine fibroid crisis.

Global Uterine Fibroids Epidemiology and Patient Flow Research Report 2021: Prevalence, Diagnosed, and Drug-treated Patients to 2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Health, Pharmaceutical, Benign neoplasms, Gynaecological neoplasia, Uterine fibroid, Clinical medicine, Medicine, Health, Uterine artery embolization

The "Global Uterine Fibroids Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Uterine Fibroids Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Uterine Fibroids Epidemiology and Patient Flow Analysis - 2021, provides Uterine Fibroids epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Uterine Fibroids patients, history of the disease at the population level (Uterine Fibroids prevalence, Uterine Fibroids incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Uterine Fibroids patients by age group, gender
    The data from this research will help executives:
    Establish basis for Uterine Fibroids market sizing, assessing market potential, and developing drug forecast models
    Identify Uterine Fibroids patients segments through age groups, gender, and disease sub-types
    Evaluate Uterine Fibroids market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005471/en/

Free From Fibroids Will Raise Awareness of all Available Treatment Options for Symptomatic Uterine Fibroids

Retrieved on: 
Wednesday, June 30, 2021
Gynaecological neoplasia, Uterine fibroid, Clinical medicine, Medicine, Health, Gynecological surgery, Surgical instruments, Uterine myomectomy, Uterine artery embolization

WASHINGTON , June 30, 2021 /PRNewswire-PRWeb/ -- Today, Free From Fibroids and the Fibroid Coalition officially launched their efforts to raise awareness of all available treatment options for uterine fibroids.

Key Points: 
  • WASHINGTON , June 30, 2021 /PRNewswire-PRWeb/ -- Today, Free From Fibroids and the Fibroid Coalition officially launched their efforts to raise awareness of all available treatment options for uterine fibroids.
  • They have assembled a group of individuals who are passionate about providing patients and physicians with non-surgical treatment options for fibroids.
  • Uterine fibroids are diagnosed roughly three times more frequently in Black women and women of color than in white women of the same age.
  • Free From Fibroids is dedicated to the following:
    To support and empower women suffering with uterine fibroids.

The Fibroid Foundation Announces the 2021 Fibroid Awareness Month Event Schedule

Retrieved on: 
Tuesday, June 29, 2021
Anatomy, Benign neoplasms, Gynaecological neoplasia, Fibroid, Uterine fibroid, Uterus, Health, Branches of biology

WASHINGTON, June 29, 2021 /PRNewswire/ -- The Fibroid Foundation announces the Fibroid Awareness Month event schedule for July 2021.

Key Points: 
  • WASHINGTON, June 29, 2021 /PRNewswire/ -- The Fibroid Foundation announces the Fibroid Awareness Month event schedule for July 2021.
  • During Fibroid Awareness Month, the programming will focus on helping the fibroid community to Live Their Best Lifeby featuring virtual segments onexercise, nutrition, legislation, research and peer-to-peer support provided by The Fibroid Foundation's chapters.
  • 2007 , introduced in The House of Representatives by Representative Yvette D. Clarke (NY-9) in March,will provide long-overdue fibroid research funding.
  • The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 will provide $150 millionto the National Institutes of Health.

ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting

Retrieved on: 
Thursday, June 24, 2021
Gynaecological neoplasia, Uterine fibroid, Endometriosis, Ticker symbol, Preterm birth, Gynaecology, Health, Clinical medicine

Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor.

Key Points: 
  • Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor.
  • ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol OBSV and on the SIX Swiss Exchange where it is trading under the ticker symbol OBSN.
  • These statements may be identified by words such as believe, expect, may, plan, potential, will, and similar expressions, and are based on ObsEvas current beliefs and expectations.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Worldwide Myomectomy Industry to 2026 - Rise in Minimally Invasive Procedures is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Surgery, Health, Gynecological surgery, Clinical medicine, Medicine, Gynaecological neoplasia, Uterine fibroid, Uterine myomectomy, Medical specialties, Surgical instruments, Morcellator, Victor Bonney

According to this, myomectomy procedures were classified under surgeries that can be delayed by several months.

Key Points: 
  • According to this, myomectomy procedures were classified under surgeries that can be delayed by several months.
  • These guidelines resulted in surgeons delaying myomectomy procedures which will impact devices used in the myomectomy market.
  • With the rise in patients with uterine fibroids, the demand for myomectomy procedures will also increase.
  • These factors along with high reimbursement rates and government initiatives contribute to North America occupying the largest share within the Myomectomy market.

Gynesonics Announces Positive Coverage Policy Decision Published by Cigna for Treatment of Uterine Fibroids with the Sonata System

Retrieved on: 
Thursday, June 3, 2021
Professional services, Health, Medical devices, Surgery, Insurance, Managed care, General Health, Medicine, Clinical medicine, Medical specialties, Gynaecological neoplasia, Uterine fibroid, Surgical oncology, Interventional radiology, Gynecological surgery, Transcervical, Radiofrequency ablation, Uterus, Ablation, Sonata System, Gynesonics, SONATA SYSTEM, GYNESONICS

The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids.

Key Points: 
  • The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids.
  • Fibroids are treated from within the uterus, so treatment with the Sonata System requires no incisions, no tissue is surgically removed, and the uterus is retained.
  • This policy opens the way for their members to have the Sonata Procedure, the least invasive radio frequency ablation treatment for uterine fibroids, said Chris Owens, President and CEO of Gynesonics.
  • Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

New Guidance from the American College of Obstetricians and Gynecologists for Fibroid Management Supports Incisionless Transcervical Radiofrequency Ablation as a Uterus-Preserving Treatment Option

Retrieved on: 
Tuesday, June 1, 2021
Surgery, Women, FDA, Clinical trials, Biotechnology, Other Health, Health, Consumer, Pharmaceutical, Medicine, Clinical medicine, Neoplasms, Interventional radiology, Gynaecological neoplasia, Uterine fibroid, Radiofrequency ablation, Transcervical, Ablation, Sonata System, Gynesonics, SONATA SYSTEM, GYNESONICS

We are pleased that ACOG included transcervical radiofrequency ablation of fibroids in their Practice Bulletin.

Key Points: 
  • We are pleased that ACOG included transcervical radiofrequency ablation of fibroids in their Practice Bulletin.
  • This comes on the heels of the two-part expert consensus recommendation of a new fibroid treatment algorithm in Europe incorporating transcervical radiofrequency ablation.
  • Im particularly pleased to see ACOG recognize the efficacy of transcervical radiofrequency ablation of fibroids.
  • Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021

Retrieved on: 
Monday, May 31, 2021
Life sciences, Health sciences, Health, Gynaecological neoplasia, Uterine fibroid, Fertility, Women's health, Preterm birth, Endometriosis, Biopharmaceutical, Pregnancy

Geneva, Switzerland andBoston, MA May 31, 2021 ObsEva SA(NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today announced that shareholders approved all Board proposals at its 2021 Annual General Meeting held on May 28, 2021.

Key Points: 
  • Geneva, Switzerland andBoston, MA May 31, 2021 ObsEva SA(NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today announced that shareholders approved all Board proposals at its 2021 Annual General Meeting held on May 28, 2021.
  • To access the AGM 2021 section of the general meetings section directly, please click her e .
  • To access the full invitation to the AGM 2021 directly, please click he r e.
    ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health and pregnancy.
  • Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor.